Migraine in Pregnancy & Breastfeeding

Migraine in Pregnancy and Breastfeeding — scientific infographic poster

If you live with migraine and you are pregnant, trying to conceive, or breastfeeding, you probably have two questions circling in your head: Will my migraines get better or worse? and What can I safely take if one hits? This article walks through both — the hormonal shifts that change migraine patterns across pregnancy and postpartum, the red flags doctors never dismiss as "just another migraine," and a practical tier of acute and preventive options with the best available safety data.

Medication decisions in pregnancy and lactation are individual and belong with the people prescribing. This page sets out the landscape: what studies, drug labels and guidelines report.

Table of Contents

  1. What Usually Changes — and Why
  2. When Migraine Does Not Improve (or Gets Worse)
  3. New-Onset Headache in Pregnancy: The Red-Flag Workup
  4. Acute Treatment Tier in Pregnancy
  5. Preventives Generally Considered Acceptable
  6. Preventives With Known Pregnancy Risks
  7. Status Migrainosus and the Emergency Department Plan
  8. Postpartum Migraine Surge and Stroke Risk
  9. Breastfeeding Compatibility
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Usually Changes — and Why

The headline statistic most neurologists quote is this: roughly 50–75% of women with migraine improve during pregnancy, with the biggest gains in the second and third trimesters. Some women stop having attacks entirely. The reason is hormonal. Estrogen levels rise steadily through pregnancy and — crucially — stay stable at high levels, rather than cycling up and down every month. Migraine brains seem to react less to a high-but-steady estrogen environment than to the sharp monthly drop that normally triggers menstrual attacks.

The first trimester is the bumpy part. Estrogen is climbing but nausea, dehydration, interrupted sleep, and the sudden stop of any preventive medication can together make the first 12 weeks feel worse, not better. If you can get through the first trimester, the second and third usually bring meaningful relief.

For more on how estrogen drives attacks, see Menstrual Migraine and Hormonal Triggers.

When Migraine Does Not Improve (or Gets Worse)

The 50–75% improvement figure hides an important subgroup: migraine with aura. Women who have aura are less likely to improve in pregnancy, and a meaningful minority get worse. A few patterns to know:

New-Onset Headache in Pregnancy: The Red-Flag Workup

Not every bad headache in pregnancy is a migraine. Pregnancy itself raises the risk of several serious conditions that can masquerade as migraine, and the stakes of missing them are very high. Obstetric and emergency teams treat any new or significantly different headache in pregnancy — especially in the second half — as needing same-day evaluation.

The main differential diagnoses to rule out:

Red-flag features that obstetric teams treat as urgent (same-day): thunderclap onset; fever; neck stiffness; new neurological deficit; seizure; visual loss; severe hypertension; the worst headache of your life; a headache that is qualitatively different from the usual pattern. Obstetric triage exists precisely for these calls.

See also Preeclampsia and Aura and Visual Disturbances.

Acute Treatment Tier in Pregnancy

When an attack does break through, there is a rough tier of options ordered from most to least safety data in pregnancy.

First line — acetaminophen (paracetamol). 500–1000 mg is the standard first-line acute treatment throughout pregnancy. Large observational datasets have raised questions about heavy, prolonged prenatal exposure and child neurodevelopment. The largest study so far, of 2,480,797 children born in Sweden (Ahlqvist and colleagues, 2024), found marginally higher risks of autism, attention-deficit/hyperactivity disorder (ADHD) and intellectual disability in simple comparisons, but no link at all when brothers and sisters were compared with each other (hazard ratios 0.98, 0.98 and 1.01), and no pattern of more risk with more use; the authors conclude that the earlier associations may have come from family factors (familial confounding). Short, episodic use for migraine is considered the safest analgesic choice, and the usual practice is the lowest effective dose for short periods rather than daily use.

Non-pharmacologic rescue. Cold packs, a dark quiet room, hydration with electrolytes, a caffeine-containing beverage (within the 200 mg/day pregnancy limit), sleep. These sound trivial but genuinely abort many attacks before they escalate.

Antiemetics. Pregnancy-associated nausea plus migraine nausea is a miserable combination. Metoclopramide and ondansetron (after the first trimester, with some caveats) are commonly used. Metoclopramide also has mild anti-migraine activity.

Triptans. Sumatriptan has the most pregnancy safety data of any triptan — pregnancy registries run by drug manufacturers and Scandinavian national databases have followed thousands of exposed pregnancies without finding a clear increase in major malformations or adverse outcomes. Since June 30, 2015, the U.S. Food and Drug Administration (FDA) Pregnancy and Lactation Labeling Rule has removed the old pregnancy letter categories (A, B, C, D and X) from prescription drug labels, replacing them with a written summary of the pregnancy data, including information from any pregnancy exposure registry. No drug is fully "proven safe" in pregnancy, but many headache specialists consider sumatriptan acceptable when acetaminophen fails, particularly if the alternative is a severe, dehydrating, intractable attack. Other triptans have less data but are probably broadly similar; sumatriptan remains the default. See Triptans and Gepants for the broader landscape.

Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, ketorolac). Can be used cautiously in the second trimester and are generally avoided in the first. Nonsteroidal anti-inflammatory drug (NSAID) labels warn against use from 30 weeks of gestation — they can cause premature closure of the fetal ductus arteriosus and oligohydramnios. In October 2020 the U.S. Food and Drug Administration extended this warning to include use from 20 weeks onward.

Ergots (ergotamine, dihydroergotamine). Contraindicated in pregnancy. They cause uterine contractions and vasoconstriction and carry known fetal risks.

Gepants (rimegepant, ubrogepant, atogepant) and ditans (lasmiditan). Human pregnancy data are insufficient, so they are not among the first-choice options.

Opioids. Generally avoided. They do not treat migraine well, are associated with medication-overuse headache, and carry neonatal withdrawal risk with regular late-pregnancy use.

Preventives Generally Considered Acceptable

When attack frequency is high enough to call for prevention during pregnancy, several options have reasonable reassuring data. None is truly risk-free, and the decision always compares the drug risk against the harm of uncontrolled severe migraine (dehydration, missed nutrition, depression, medication overuse).

Preventives With Known Pregnancy Risks

Status Migrainosus and the Emergency Department Plan

Status migrainosus — a debilitating migraine lasting more than 72 hours — happens in pregnancy too, and obstetric and emergency teams treat it as a reason for hospital evaluation. Severe dehydration, ketosis, and inability to eat are themselves risks to the pregnancy. Obstetric or emergency evaluation allows the team to:

Postpartum Migraine Surge and Stroke Risk

The protective estrogen bath ends abruptly at delivery. Within the first week postpartum, estrogen drops from pregnancy levels back toward baseline, and many women experience a sharp postpartum migraine surge. Roughly a third of women who improved in pregnancy have an attack within the first week after delivery, and more over the first month. Sleep deprivation, dehydration from breastfeeding, and the huge hormonal swing all contribute.

Two safety points matter here:

Breastfeeding Compatibility

The U.S. National Library of Medicine's LactMed database is the gold-standard free resource for breastfeeding medication questions. A quick summary for migraine drugs:

As a rule of thumb, if a drug is broadly acceptable in pregnancy it is usually acceptable in breastfeeding too, often more so because the baby's exposure through milk is typically smaller than across the placenta.

Key Research Papers

  1. Negro A, Delaruelle Z, Ivanova TA, et al. Headache and pregnancy: a systematic review. J Headache Pain. 2017;18(1):106. — doi:10.1186/s10194-017-0816-0
  2. MacGregor EA. Migraine in pregnancy and lactation. Neurol Sci. 2014;35 Suppl 1:61–4. — doi:10.1007/s10072-014-1744-2
  3. Amundsen S, Nordeng H, Nezvalová Henriksen K, et al. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol. 2015;11(4):209–19. — doi:10.1038/nrneurol.2015.29
  4. Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population-based case-control study. BMJ. 2009;338:b664. — doi:10.1136/bmj.b664
  5. Ropper AH, Klein JP. Cerebral venous thrombosis. N Engl J Med. 2021;385(1):59–64. — doi:10.1056/NEJMra2106545
  6. Ahlqvist VH, Sjöqvist H, Dalman C, et al. Acetaminophen use during pregnancy and children's risk of autism, ADHD, and intellectual disability. JAMA. 2024;331(14):1205–1214. — doi:10.1001/jama.2024.3172
  7. Hernández-Díaz S, Straub L, Bateman BT, et al. Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure. N Engl J Med. 2024;390(12):1069–1079. — doi:10.1056/NEJMoa2309359
  8. Noseda R, Bedussi F, Gobbi C, et al. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase. J Headache Pain. 2024;25(1):10. — doi:10.1186/s10194-024-01715-4
  9. U.S. Food and Drug Administration. Pregnancy and Lactation Labeling (Drugs) Final Rule. — fda.gov

PubMed Topic Searches

The following PubMed topic searches return current peer-reviewed work on migraine management across pregnancy, lactation, and the postpartum period:

  1. PubMed: Migraine course in pregnancy and estrogen
  2. PubMed: Sumatriptan pregnancy registry outcomes
  3. PubMed: Topiramate and cleft lip/palate in pregnancy
  4. PubMed: Valproate and neural tube defects
  5. PubMed: Migraine with aura and stroke in pregnancy
  6. PubMed: Preeclampsia headache and differential diagnosis
  7. PubMed: Cerebral venous sinus thrombosis and postpartum
  8. PubMed: NSAIDs in pregnancy and ductus arteriosus closure
  9. PubMed: CGRP monoclonal antibodies in pregnancy
  10. PubMed: Migraine medications in breastfeeding and LactMed

Back to Table of Contents

Connections

Back to Table of Contents